WhatPeptide

PT-141

A melanocortin receptor agonist approved as bremelanotide for hypoactive sexual desire disorder in premenopausal women.

Strong evidence FDA Approved Sexual Health

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

Half-life

About 2.7 hours

Dosage range

1.75 mg as-needed SC; max 1 dose/24h, 8 doses/month

Administration

Subcutaneous injection

Research level

Strong

How PT-141 works

PT-141 activates central melanocortin receptors (primarily MC4R pathway) involved in sexual arousal and desire signaling. Unlike PDE5 inhibitors, it acts through central neurochemical circuits rather than peripheral vasodilation alone. Blood pressure effects and nausea risk are clinically relevant.

Also known as: Bremelanotide, Vyleesi

Research relevance

Sexual Health
Strong research relevance 95

Side effects & safety

Nausea Flushing Headache Transient blood pressure rise Hyperpigmentation at injection site Max 1 dose per 24 hours, 8 doses per month per FDA label

Contraindications

Uncontrolled hypertension
Cardiovascular disease risk
Pregnancy

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is PT-141? +
A melanocortin receptor agonist approved as bremelanotide for hypoactive sexual desire disorder in premenopausal women. Its mechanism of action is supported by robust clinical evidence.
What is PT-141 researched for? +
PT-141 has the strongest research relevance for Sexual Health. Evidence is supported by robust clinical evidence.
What are the side effects of PT-141? +
Reported side effects include Nausea, Flushing, Headache, Transient blood pressure rise, Hyperpigmentation at injection site, Max 1 dose per 24 hours, 8 doses per month per FDA label. Key contraindications: Uncontrolled hypertension; Cardiovascular disease risk; Pregnancy.
Is PT-141 FDA approved? +
Yes, PT-141 has FDA approval for specific indications. Always consult a healthcare provider for appropriate use.
How is PT-141 administered? +
PT-141 is typically administered via subcutaneous route. Researched dosage range: 1.75 mg as-needed SC; max 1 dose/24h, 8 doses/month. Half-life: About 2.7 hours.

Explore similar peptides

Kisspeptin-10

Moderate evidence

Sexual Health

Kisspeptin-10 is the biologically active C-terminal decapeptide fragment of kisspeptin, a hypothalamic neuropeptide that acts as the master regulator of GnRH pulse generation and the HPG axis. It is studied for stimulating reproductive hormones and enhancing sexual motivation and arousal. Placed on FDA Category 2 list (September 29, 2023).

MT-2

Moderate evidence

Sexual Health

Melanotan II is a synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH) studied for skin tanning, erectile dysfunction, and reduced appetite through melanocortin receptor agonism. Notable for its significant side effect profile including nausea, facial flushing, and changes in existing moles. Placed on FDA Category 2 list (September 29, 2023) as 'Melanotan II.'

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

Gonadorelin

Strong evidence

GnRH Analog

A synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH-I). FDA-approved historically as Factrel (diagnostic, 1978) and Lutrepulse (NDA 019687, hypothalamic amenorrhea, 1989) — both now discontinued. Currently available through compounding pharmacies as an HCG alternative.